A 28-year-old man with a family history of early-onset colorectal cancer (age 35) and endometrial cancer (age 42) undergoes genetic counseling. Molecular testing identifies a heterozygous mutation in the MLH1 gene (mismatch repair gene). Colonoscopy shows no current lesions. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer, HNPCC) **Key Point:** MLH1 mutations cause defective mismatch repair (MMR), leading to microsatellite instability (MSI-H). Lynch syndrome confers a 70–80% lifetime risk of colorectal cancer and 40–60% risk of endometrial cancer. Early surveillance and family counseling are the cornerstones of management. ## Mismatch Repair Defect in Lynch Syndrome **High-Yield:** The MMR pathway corrects single base-pair mismatches and insertion/deletion loops arising during DNA replication. Key proteins include: - **MLH1, MSH2, MSH6, PMS2** — form recognition and repair complexes - Deficiency → accumulation of mutations → microsatellite instability → early-onset, often right-sided colorectal cancers **Mnemonic:** **MLH1/MSH2 = MisMatch repair Loss** — the two most commonly mutated genes in Lynch syndrome. ## Management Strategy: Intensive Surveillance + Family Cascade The most appropriate immediate action is **initiation of surveillance colonoscopy every 1–2 years AND referral for genetic counseling of first-degree relatives**. This achieves: 1. **Early detection of colorectal cancer** — colonoscopy every 1–2 years (vs. 10 years in average-risk individuals) detects cancers at earlier, more curable stages 2. **Prevention of metachronous cancers** — polypectomy of adenomas prevents progression 3. **Family cascade screening** — 50% of first-degree relatives inherit the mutation; identifying them allows early surveillance 4. **Gynecological surveillance** — women require transvaginal ultrasound ± endometrial biopsy annually starting age 30–35 to detect endometrial cancer early **Clinical Pearl:** Lynch syndrome accounts for 2–4% of all colorectal cancers. Colonoscopy every 1–2 years reduces colorectal cancer incidence by ~70% and mortality by ~65% compared to no surveillance. ## Why Other Options Fail | Option | Why Incorrect | |--------|---------------| | Aspirin + 10-year colonoscopy | Aspirin may reduce cancer risk in some studies but is not standard first-line; 10-year intervals are far too long for Lynch syndrome (cancer risk is 70–80% lifetime, not 5–10%) | | Total proctocolectomy | Prophylactic colectomy is not indicated in the absence of current cancer or multiple advanced adenomas; surveillance is the standard approach | | Adjuvant chemotherapy | Chemotherapy is for treatment of established cancer, not prevention in asymptomatic individuals; it has no role in cancer prevention | ## Surveillance Protocol for Lynch Syndrome ```mermaid flowchart TD A[MLH1 Mutation Identified]:::outcome --> B[Initiate Surveillance]:::action B --> C[Colonoscopy every 1-2 years]:::action B --> D[Gynecological surveillance for women]:::action B --> E[Genetic counseling of relatives]:::action D --> F[Transvaginal ultrasound annually]:::action D --> G[Endometrial biopsy if thickening]:::action E --> H[Cascade testing of first-degree relatives]:::action H --> I[Relatives with mutation → surveillance]:::action H --> J[Relatives without mutation → standard screening]:::outcome ```